In this free webinar, see how DPYD testing can be implemented from guidelines to go-live through practical pharmacogenomics (PGx) reporting and workflow design. The featured speakers will share ...

HOUSTON, Oct. 16, 2025 /PRNewswire/ -- Oncologists and pharmacy experts are reacting to last week's Food and Drug Administration warning that requires genetic testing on patients receiving the common ...

The YouScript CEO discusses new FDA guidance. FDA recently announced new safety requirements for DPD screening in cancer patients. Kristine Ashcraft, founder and CEO of YouScript, spoke with ...

National clinical guidelines don’t mention screening cancer patients for DPYD gene variants, but hospital pharmacy leaders are forging ahead with the patient safety practice, the American Society of ...

Genomic medicine leverages an individual’s genetic information to guide healthcare decisions, with drug-gene testing (also known as pharmacogenomics, or PGx) being a key application that personalizes ...

5-Fluorouracil (5-FU) and capecitabine are fluoropyrimidine chemotherapies that are used to treat a range of solid tumours including breast, pancreatic, stomach and colorectal. Metabolism of ...

A prospective trial of gastrointestinal cancer patients showed the feasibility of preemptive genetic testing for DPYD/UGT1A1 variants associated with increased chemotherapy toxicity. Genotype-guided ...

5-fluorouracil (5-FU) and its oral analog capecitabine are fluoropyrimidine chemotherapy agents used in several solid tumors. Approximately 5% of patients inherit diminished or null activity genetic ...

A man in his early 70s died after adjuvant chemotherapy due to fulminant gastrointestinal toxicity and bowel ischaemia linked to an undetected dihydropyrimidine dehydrogenase (DPYD) deficiency, ...

Aranscia® solutions help oncologists comply with new FDA warning label requiring DPYD genetic testing in patients receiving select chemotherapies HOUSTON, Oct. 16, 2025 /PRNewswire/ -- Oncologists and ...